Over the past year, data from separate vaccine rollouts in Wales, Australia, Canada and the US suggests it can delay the onset of dementia, slow down its progress and cut the risk of death among those already diagnosed. Despite the vaccine being aimed at the over-50s, the 39-year-old researcher leading some of the analyses is so convinced by the data that he has had the jab himself.